Danegaptide is primarily researched for its potential cardioprotective effects, particularly in the context of myocardial infarction and ischemia-reperfusion injury. It functions as a gap junction modifier, aiming to preserve cell-to-cell communication during cardiac stress, which may reduce tissue damage and improve heart function post-injury. Studies suggest it could be beneficial in minimizing infarct size and enhancing recovery in patients undergoing cardiac surgeries or experiencing heart attacks. Its application is still largely experimental, with ongoing clinical trials to evaluate its efficacy and safety in human subjects.